Biopharma deal activity accelerated in July, with total year-to-date deal value reaching $186.69 billion through the first seven months of 2026—up 13% versus the comparable 2025 period. July contributed $16.58 billion, following particularly large deal months earlier in the year. The update frames a market where transaction appetite remains high despite volatility, suggesting continued willingness among strategics to acquire late-stage assets and platform capabilities. It also points to sustained liquidity for companies with defensible IP, differentiated clinical data, or scalable manufacturing footprints. For deal-making teams, the implication is clear: competition for attractive assets remains intense, and diligence timelines are likely under pressure to match deal pace.